Your session is about to expire
← Back to Search
HEMOTAG with Standard of Care in DM patients for Type 2 Diabetes (PRIZETAG Trial)
N/A
Recruiting
Research Sponsored by Aventusoft, LLC.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Summary
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
Eligible Conditions
- Type 2 Diabetes
- Stroke
- Peripheral Arterial Disease
- Coronary Artery Disease
- Cardiovascular Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.
Secondary study objectives
All Deaths for 12 months
Correlation of AO and CE at 6 and 12 months
Correlation of CTI and CE at 6 and 12 months
+6 moreOther study objectives
All cause hospitalizations
Health Status as measured by the LVD-36
Health care resource utilization
+2 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: HEMOTAG with Standard of Care in DM patientsExperimental Treatment1 Intervention
HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.
Find a Location
Who is running the clinical trial?
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,889 Previous Clinical Trials
47,834,092 Total Patients Enrolled
Aventusoft, LLC.Lead Sponsor
1 Previous Clinical Trials
420 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger